In 2007, SCN secured the world-wide rights to the natural antiviral substance NGNA, for both human and animal treatments, reports BusinessWire. According to BusinessWire, recent studies, both in advanced laboratories and on mice, have shown that NGNA has good effect on many common viruses that affect humans. SCN now wants to find out if NGNA has the same positive effect on viruses that affect animals, since animal farming is a significant market, and there are few – if any – natural products available today.
“Our studies on mice have shown that NGNA is well tolerated and that the substance has both generic antiviral effects and good results on specific viruses, even dangerous bird flu-like ones. Our main focus will be on developing NGNA against rhinovirus, but with these positive results, is natural for us to look for new and interesting possibilities, both for human and animal use.
"Viral disease has a great impact on animal farming, as in any environment where many individuals share a limited space. If we can provide a natural compound as a solution, or part of a solution, for such a significant industry, that would be very interesting”, says Dan Edwall, VP R&D at SCN.